Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety

Phase 1 Completed 96 enrolled Alpine Immune Sciences, Inc. Clinical Network Services (CNS) Pty Ltd · collab

RandomizedParallel-groupDouble-blindOther

Summary

This study is testing the safety, tolerability, pharmacokinetics (PK--the amount of study drug in the blood), pharmacodynamics (PD), how the study drug affects the body) and immunogenicity (how the study drug affects the immune system) of single and multiple doses and dose levels of an investigational drug called ALPN-101.

Timeline

Start: 2019-01-29
Primary completion: 2019-11-18
Completion: 2019-11-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	ACAZICOLCEPT	Protein / enzyme biologic	—	Intravenous

Indications

No indication recorded.